

Muna Qayed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9692521/publications.pdf>

Version: 2024-02-01

37
papers

5,745
citations

471509

17
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

7784
citing authors

#	ARTICLE	IF	CITATIONS
1	Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. <i>Blood Advances</i> , 2022, 6, 746-749.	5.2	18
2	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	5.0	70
3	Blinatumomab induces complete response in refractory PTLN after hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 3058-3061.	5.2	4
4	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	1.6	79
5	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	5.2	9
6	Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel. <i>Journal of Clinical Oncology</i> , 2022, 40, 10016-10016.	1.6	0
7	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 137, 983-993.	1.4	20
8	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	1.6	111
9	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	1.2	10
10	Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8 ⁺ T cells drive gastrointestinal acute graft-versus-host disease. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	39
11	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	1.4	4
12	Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia. <i>Frontiers in Pediatrics</i> , 2021, 9, 784377.	1.9	2
13	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
14	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
15	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. <i>Blood</i> , 2020, 136, 42-44.	1.4	8
16	Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd. <i>Blood</i> , 2020, 136, 38-39.	1.4	0
17	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
18	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
20	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
21	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	5.2	63
22	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	27.0	3,680
23	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
24	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
25	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2018, 24, 1504-1506.	30.7	393
26	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	5.2	13
27	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	1.4	0
28	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
29	Building blocks for institutional preparation of CTL019 delivery. <i>Cytotherapy</i> , 2017, 19, 1015-1024.	0.7	61
30	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	5.0	166
31	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
32	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1273-1277.	2.0	24
33	InÂVivo T Cell Costimulation Blockade with Abatacept forÂAcute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1638-1649.	2.0	96
34	A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD. <i>Blood</i> , 2012, 120, 741-741.	1.4	1
35	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. <i>Blood</i> , 2011, 118, 3074-3074.	1.4	0
36	Platelet Transfusion Requirements Are Associated with Endothelial Cell Injury and Angiogenesis During Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3487-3487.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Hypercalcemia in Pediatric Acute Megakaryocytic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 373-376.	0.6	9